Wells Fargo
MNPR icon

Wells Fargo’s Monopar Therapeutics MNPR Stock Holding History

Wells Fargo’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$94.7K Sell
1,728
-3,397
-66% -$205K ﹤0.01% 5130
2025
Q4 		$335K Buy
5,125
+2,804
+121% +$229K ﹤0.01% 4764
2025
Q3 		$190K Buy
2,321
+20
+0.9% +$894 ﹤0.01% 4958
2025
Q2 		$82.3K Buy
2,301
+2,051
+820% +$74.5K ﹤0.01% 5307
2025
Q1 		$9.1K Hold
250
– – ﹤0.01% 5901
2024
Q4 		$5.5K Sell
250
-250
-50% -$4.2K ﹤0.01% 6046
2024
Q3 		$3.37K Hold
500
– – ﹤0.01% 5992
2024
Q2 		$1.82K Buy
500
+193
+63% +$679 ﹤0.01% 6029
2024
Q1 		$1.05K Buy
307
+300
+4,286% +$894 ﹤0.01% 6139
2023
Q4 		$13 Hold
7
– – ﹤0.01% 7329
2023
Q3 		$20 Hold
7
– – ﹤0.01% 7201
2023
Q2 		$28 Buy
7
+1
+17% +$5 ﹤0.01% 7212
2023
Q1 		$43 Hold
6
– – ﹤0.01% 7147
2022
Q4 		$73 Hold
6
– – ﹤0.01% 6882
2022
Q3 		$0 Hold
6
– – ﹤0.01% 7098
2022
Q2 		$0 Buy
6
+1
+20% +$11 ﹤0.01% 7228
2022
Q1 		$0 Hold
5
– – ﹤0.01% 7531
2021
Q4 		$0 Hold
5
– – ﹤0.01% 7591
2021
Q3 		$0 Hold
5
– – ﹤0.01% 7306
2021
Q2 		$0 Buy
5
+1
+25% +$29 ﹤0.01% 7229
2021
Q1 		$0 Hold
4
– – ﹤0.01% 7191
2020
Q4 		$0 Buy
4
+1
+33% +$26 ﹤0.01% 6807
2020
Q3 		$0 Buy
+3
New +$97 ﹤0.01% 6673

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wells Fargo's MNPR Position: Q1 2026 in Review

Wells Fargo reduced its Monopar Therapeutics (MNPR) stake by 66% in Q1 2026, selling an estimated $205K and leaving 1,728 shares worth $94.7K. The position accounts for ﹤0.01% of the portfolio, ranked #5130.

Wells Fargo first reported a position in MNPR in Q3 2020 and has held it in 23 quarters since. The position peaked at $335K in Q4 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Wells Fargo held 1,728 shares of Monopar Therapeutics worth $94.7K as of Q1 2026.
  • Wells Fargo sold 3,397 Monopar Therapeutics shares in Q1 2026, an estimated $205K.
  • Monopar Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5130 holding.
  • Wells Fargo first reported a position in Monopar Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Wells Fargo's Monopar Therapeutics position peaked at $335K in Q4 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.